Astria Therapeutics discovers and develops innovative drugs for treating inflammatory conditions.
Catabasis Pharmaceuticals is a biopharmaceutical company located in Cambridge, Massachusetts focused on the discovery and development of innovative drugs to treat inflammatory conditions. Their platform technology enables the discovery and development of small molecules that simultaneously and specifically target pathways in the inflammatory response. The Catabasis platform will lead to the development of a novel mechanism of action therapies to safely and effectively treat inflammatory diseases.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 15, 2022 | Post-IPO Equity | $100M | — | — | — | Detail |
Feb 8, 2021 | Post-IPO Equity | $110.01M | — | — | — | Detail |
Jan 29, 2020 | Post-IPO Equity | $26.50M | — | — | — | Detail |
Jun 22, 2018 | Post-IPO Equity | $42M | — | — | — | Detail |
Sep 28, 2016 | Post-IPO Equity | $11.50M | — | — | — | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
May 5, 2020
Dazzle Rocks
|
Series A | $6.80M | MMO Games | — |
Sep 3, 2019
Dreamdata
|
Pre-seed | $535K | Analytics | — |
Jul 18, 2018
FRVR
|
Seed | $3M | Android | — |
Oct 7, 2017
Lix Technologies
|
Series A | $5.40M | E-Learning | Yes |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Lightstone Ventures | Yes | Series B |
Advanced Technology Ventures | — | Series B |
Clarus Ventures | — | Series B |
MedImmune Ventures | — | Series B |
SV Health Investors | — | Series B |
Astria Therapeutics has acquired 1 organizations. Their most recent acquisition was Quellis Biosciences on Jan 29, 2021. They acquired Quellis Biosciences for 0.
Date
Company Name
|
Industry | Acquisition Type | Price | |
---|---|---|---|---|
Jan 29, 2021
Quellis Biosciences
|
Biotechnology | acquisition | — | Detail |